Michael P. Stehn
Corporate Officer/Principal chez Parenteral Drug Association
Profil
Michael P.
Stehn is a Member of the Parenteral Drug Association.
He was previously the Director of Quality Assurance & Regulatory Compliance at The Rugby Group, Inc. and the Senior Vice President of Operations at Akorn, Inc. from 1990 to 2020.
He obtained an undergraduate degree from Fairleigh Dickinson University.
Currently, Mr. Stehn holds a job at Parenteral Drug Association.
Postes actifs de Michael P. Stehn
| Sociétés | Poste | Début |
|---|---|---|
| Parenteral Drug Association | Corporate Officer/Principal | - |
Anciens postes connus de Michael P. Stehn
| Sociétés | Poste | Fin |
|---|---|---|
| AKORN, INC. | Directeur des opérations | 05/09/2012 |
The Rugby Group, Inc.
 The Rugby Group, Inc. Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., The Rugby Group, Inc. is a company that develops and manufactures generic drugs. The company is based in Parsippany, NJ. The Rugby Group was acquired by Actavis, Inc. from Hoechst AG on August 26, 1997 for $70 million. | Corporate Officer/Principal | - |
Formation de Michael P. Stehn
| Fairleigh Dickinson University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Akorn, Inc.
 Akorn, Inc. Pharmaceuticals: MajorHealth Technology Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It manufactures and markets branded and generic products including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The company was founded in 1971 and is headquartered in Lake Forest, IL. | Health Technology |
The Rugby Group, Inc.
The Rugby Group, Inc. Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., The Rugby Group, Inc. is a company that develops and manufactures generic drugs. The company is based in Parsippany, NJ. The Rugby Group was acquired by Actavis, Inc. from Hoechst AG on August 26, 1997 for $70 million. | Health Technology |
| Parenteral Drug Association |
